Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hafnia alvei HA4597
- Development stage
- Unknown
- Lead developer
- TargEDys
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Hafnia alvei HA4597 is a precision probiotic strain developed by TargEDys (now Biocodex) for the management of obesity and overweight. The strain, originally isolated from raw milk cheese, functions as a live biotherapeutic that produces Caseinolytic peptidase B (ClpB). ClpB is a bacterial protein that acts as a molecular mimetic of the human satiety hormone alpha-melanocyte-stimulating hormone (α-MSH). By mimicking α-MSH, ClpB interacts with the melanocortin 4 receptor (MC4R) in the hypothalamus, part of the gut-brain axis, to induce feelings of fullness and regulate appetite. Marketed under brand names such as EnteroSatys and Satylia, clinical trials have shown that HA4597 significantly enhances weight loss and improves metabolic parameters like hip circumference and glycemic control in overweight individuals.
- Brand names
- EnteroSatysSatylia
- Other names
- ProbioSatysClpB-producing Hafnia alvei HA4597
02
Targets
MC4R (Melanocortin 4 receptor)
Beyond the preview
Go deeper on Hafnia alvei HA4597.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hafnia alvei HA4597.